{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T03:29:11Z","timestamp":1776223751426,"version":"3.50.1"},"reference-count":133,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2022,2,12]],"date-time":"2022-02-12T00:00:00Z","timestamp":1644624000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Norte Portugal Regional Operational Programme, PORTUGAL 2020, FEDER","award":["Norte-01-0145-FEDER-000051"],"award-info":[{"award-number":["Norte-01-0145-FEDER-000051"]}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia","doi-asserted-by":"publisher","award":["PTDC\/MEC-ONC\/0491\/2021"],"award-info":[{"award-number":["PTDC\/MEC-ONC\/0491\/2021"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia","doi-asserted-by":"publisher","award":["SFRH\/BD\/137896\/2018"],"award-info":[{"award-number":["SFRH\/BD\/137896\/2018"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Innovative strategies have been proposed to increase drug delivery to the tumor site and avoid cytotoxicity, improving the therapeutic efficacy of well-established anti-cancer drugs. Alterations in normal glycosylation processes are frequently observed in cancer cells and the resulting cell surface aberrant glycans can be used as direct molecular targets for drug delivery. In the present review, we address the development of strategies, such as monoclonal antibodies, antibody\u2013drug conjugates and nanoparticles that specific and selectively target cancer-associated glycans in tumor cells. The use of nanoparticles for drug delivery encompasses novel applications in cancer therapy, including vaccines encapsulated in synthetic nanoparticles and specific nanoparticles that target glycoproteins or glycan-binding proteins. Here, we highlight their potential to enhance targeting approaches and to optimize the delivery of clinically approved drugs to the tumor microenvironment, paving the way for improved personalized treatment approaches with major potential importance for the pharmaceutical and clinical sectors.<\/jats:p>","DOI":"10.3390\/cancers14040911","type":"journal-article","created":{"date-parts":[[2022,2,13]],"date-time":"2022-02-13T20:32:30Z","timestamp":1644784350000},"page":"911","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Glycans as Targets for Drug Delivery in Cancer"],"prefix":"10.3390","volume":"14","author":[{"given":"Francisca","family":"Diniz","sequence":"first","affiliation":[{"name":"i3S\u2014Instituto de Investiga\u00e7\u00e3o e Inova\u00e7\u00e3o em Sa\u00fade, Universidade do Porto, 4200-135 Porto, Portugal"},{"name":"IPATIMUP\u2014Institute of Molecular Pathology and Immunology, University of Porto, 4200-135 Porto, Portugal"},{"name":"ICBAS\u2014Instituto de Ci\u00eancias Biom\u00e9dicas Abel Salazar, Universidade do Porto, 4050-313 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7959-3667","authenticated-orcid":false,"given":"Pedro","family":"Coelho","sequence":"additional","affiliation":[{"name":"i3S\u2014Instituto de Investiga\u00e7\u00e3o e Inova\u00e7\u00e3o em Sa\u00fade, Universidade do Porto, 4200-135 Porto, Portugal"},{"name":"IPATIMUP\u2014Institute of Molecular Pathology and Immunology, University of Porto, 4200-135 Porto, Portugal"},{"name":"ICBAS\u2014Instituto de Ci\u00eancias Biom\u00e9dicas Abel Salazar, Universidade do Porto, 4050-313 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8641-8368","authenticated-orcid":false,"given":"Henrique O.","family":"Duarte","sequence":"additional","affiliation":[{"name":"i3S\u2014Instituto de Investiga\u00e7\u00e3o e Inova\u00e7\u00e3o em Sa\u00fade, Universidade do Porto, 4200-135 Porto, Portugal"},{"name":"IPATIMUP\u2014Institute of Molecular Pathology and Immunology, University of Porto, 4200-135 Porto, Portugal"}]},{"given":"Bruno","family":"Sarmento","sequence":"additional","affiliation":[{"name":"i3S\u2014Instituto de Investiga\u00e7\u00e3o e Inova\u00e7\u00e3o em Sa\u00fade, Universidade do Porto, 4200-135 Porto, Portugal"},{"name":"INEB\u2014Instituto Nacional de Engenharia Biom\u00e9dica, Universidade do Porto, 4200-135 Porto, Portugal"},{"name":"CESPU\u2014Instituto de Investiga\u00e7\u00e3o e Forma\u00e7\u00e3o Avan\u00e7ada em Ci\u00eancias e Tecnologias da Sa\u00fade, 4585-116 Gandra, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0286-6639","authenticated-orcid":false,"given":"Celso A.","family":"Reis","sequence":"additional","affiliation":[{"name":"i3S\u2014Instituto de Investiga\u00e7\u00e3o e Inova\u00e7\u00e3o em Sa\u00fade, Universidade do Porto, 4200-135 Porto, Portugal"},{"name":"IPATIMUP\u2014Institute of Molecular Pathology and Immunology, University of Porto, 4200-135 Porto, Portugal"},{"name":"ICBAS\u2014Instituto de Ci\u00eancias Biom\u00e9dicas Abel Salazar, Universidade do Porto, 4050-313 Porto, Portugal"},{"name":"Department of Pathology, Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8832-2703","authenticated-orcid":false,"given":"Joana","family":"Gomes","sequence":"additional","affiliation":[{"name":"i3S\u2014Instituto de Investiga\u00e7\u00e3o e Inova\u00e7\u00e3o em Sa\u00fade, Universidade do Porto, 4200-135 Porto, Portugal"},{"name":"IPATIMUP\u2014Institute of Molecular Pathology and Immunology, University of Porto, 4200-135 Porto, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2022,2,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: The next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/mco2.55","article-title":"Molecular mechanisms of chemo- and radiotherapy resistance and the potential implications for cancer treatment","volume":"2","author":"Liu","year":"2021","journal-title":"MedComm"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/nrd4664","article-title":"Assessing the relative efficacy of new drugs: An emerging opportunity","volume":"14","author":"Eichler","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/j.clinthera.2016.03.026","article-title":"Current Challenges in Cancer Treatment","volume":"38","author":"Zugazagoitia","year":"2016","journal-title":"Clin. Ther."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.semcancer.2019.11.002","article-title":"Specific targeting cancer cells with nanoparticles and drug delivery in cancer therapy","volume":"69","author":"Raj","year":"2021","journal-title":"Semin. Cancer Biol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ccell.2019.06.006","article-title":"Glycosylation in the Era of Cancer-Targeted Therapy: Where Are We Heading?","volume":"36","author":"Mereiter","year":"2019","journal-title":"Cancer Cell"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41573-020-00093-1","article-title":"The clinical impact of glycobiology: Targeting selectins, Siglecs and mammalian glycans","volume":"20","author":"Smith","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_8","unstructured":"Varki, A., Cummings, R.D., Esko, J.D., Stanley, P., Hart, G.W., Aebi, M., Darvill, A.G., Kinoshita, T., Packer, N.H., and Prestegard, J.H. (2015). Cellular Organization of Glycosylation. Essentials of Glycobiology, Cold Spring Harbor Laboratory Press."},{"key":"ref_9","unstructured":"Varki, A., Cummings, R.D., Esko, J.D., Stanley, P., Hart, G.W., Aebi, M., Darvill, A.G., Kinoshita, T., Packer, N.H., and Prestegard, J.H. (2015). N-Glycans. Essentials of Glycobiology, Cold Spring Harbor Laboratory Press."},{"key":"ref_10","unstructured":"Varki, A., Cummings, R.D., Esko, J.D., Stanley, P., Hart, G.W., Aebi, M., Darvill, A.G., Kinoshita, T., Packer, N.H., and Prestegard, J.H. (2015). O-GalNAc Glycans. Essentials of Glycobiology, Cold Spring Harbor Laboratory Press."},{"key":"ref_11","unstructured":"Varki, A., Cummings, R.D., Esko, J.D., Stanley, P., Hart, G.W., Aebi, M., Darvill, A.G., Kinoshita, T., Packer, N.H., and Prestegard, J.H. (2015). Glycosphingolipids. Essentials of Glycobiology, Cold Spring Harbor Laboratory Press."},{"key":"ref_12","unstructured":"Varki, A., Cummings, R.D., Esko, J.D., Stanley, P., Hart, G.W., Aebi, M., Darvill, A.G., Kinoshita, T., Packer, N.H., and Prestegard, J.H. (2015). Proteoglycans and Sulfated Glycosaminoglycans. Essentials of Glycobiology, Cold Spring Harbor Laboratory Press."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/nrc3982","article-title":"Glycosylation in cancer: Mechanisms and clinical implications","volume":"15","author":"Pinho","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/s41580-020-00294-x","article-title":"Global view of human protein glycosylation pathways and functions","volume":"21","author":"Schjoldager","year":"2020","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1146\/annurev-pathol-012414-040438","article-title":"Protein glycosylation in cancer","volume":"10","author":"Stowell","year":"2015","journal-title":"Annu. Rev. Pathol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13048-018-0385-0","article-title":"Sialylation of EGFR by the ST6Gal-I sialyltransferase promotes EGFR activation and resistance to gefitinib-mediated cell death","volume":"11","author":"Britain","year":"2018","journal-title":"J. Ovarian Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1016\/j.bbagen.2015.12.016","article-title":"Glycomic analysis of gastric carcinoma cells discloses glycans as modulators of RON receptor tyrosine kinase activation in cancer","volume":"1860","author":"Mereiter","year":"2016","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3719","DOI":"10.1038\/s41388-021-01801-w","article-title":"ST6Gal1 targets the ectodomain of ErbB2 in a site-specific manner and regulates gastric cancer cell sensitivity to trastuzumab","volume":"40","author":"Duarte","year":"2021","journal-title":"Oncogene"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s13402-021-00606-z","article-title":"Terminal \u03b12,6-sialylation of epidermal growth factor receptor modulates antibody therapy response of colorectal cancer cells","volume":"44","author":"Rodrigues","year":"2021","journal-title":"Cell Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Gomes, C., Osorio, H., Pinto, M.T., Campos, D., Oliveira, M.J., and Reis, C.A. (2013). Expression of ST3GAL4 leads to SLe(x) expression and induces c-Met activation and an invasive phenotype in gastric carcinoma cells. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0066737"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1093\/glycob\/cwr182","article-title":"Control of mucin-type O-glycosylation: A classification of the polypeptide GalNAc-transferase gene family","volume":"22","author":"Bennett","year":"2012","journal-title":"Glycobiology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3233\/CBM-130375","article-title":"The Cosmc connection to the Tn antigen in cancer","volume":"14","author":"Ju","year":"2014","journal-title":"Cancer Biomark"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3586","DOI":"10.1074\/jbc.M511826200","article-title":"The ST6GalNAc-I sialyltransferase localizes throughout the Golgi and is responsible for the synthesis of the tumor-associated sialyl-Tn O-glycan in human breast cancer","volume":"281","author":"Sewell","year":"2006","journal-title":"J. Biol. Chem."},{"key":"ref_24","first-page":"1443","article-title":"ST6GalNAc-I controls expression of sialyl-Tn antigen in gastrointestinal tissues","volume":"3","author":"Marcos","year":"2011","journal-title":"Front. Biosci."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"435","DOI":"10.3390\/biom2040435","article-title":"Sialyl-tn in cancer: (how) did we miss the target?","volume":"2","author":"Julien","year":"2012","journal-title":"Biomolecules"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Munkley, J. (2016). The Role of Sialyl-Tn in Cancer. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17030275"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"E4066","DOI":"10.1073\/pnas.1406619111","article-title":"Immature truncated O-glycophenotype of cancer directly induces oncogenic features","volume":"111","author":"Radhakrishnan","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"6885","DOI":"10.1111\/jcmm.14572","article-title":"Truncated O-glycans promote epithelial-to-mesenchymal transition and stemness properties of pancreatic cancer cells","volume":"23","author":"Thomas","year":"2019","journal-title":"J. Cell Mol. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.ebiom.2019.01.017","article-title":"O-glycans truncation modulates gastric cancer cell signaling and transcription leading to a more aggressive phenotype","volume":"40","author":"Freitas","year":"2019","journal-title":"EBioMedicine"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1038\/bjc.1994.486","article-title":"Expression of sialyl-Tn predicts the effect of adjuvant chemotherapy in node-positive breast cancer","volume":"70","author":"Miles","year":"1994","journal-title":"Br. J. Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1002\/1873-3468.13432","article-title":"O-glycan truncation enhances cancer-related functions of CD44 in gastric cancer","volume":"593","author":"Mereiter","year":"2019","journal-title":"FEBS Lett."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.canlet.2006.08.010","article-title":"Biological significance of cancer-associated sialyl-Tn antigen: Modulation of malignant phenotype in gastric carcinoma cells","volume":"249","author":"Pinho","year":"2007","journal-title":"Cancer Lett."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1093\/glycob\/cwaa008","article-title":"The manifold roles of sialic acid for the biological functions of endothelial glycoproteins","volume":"30","author":"Frey","year":"2020","journal-title":"Glycobiology"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1749-6632.1994.tb12043.x","article-title":"Role of selectins in leukocyte adhesion to platelets and endothelium","volume":"714","author":"McEver","year":"1994","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1093\/cvr\/cvv154","article-title":"Selectins: Initiators of leucocyte adhesion and signalling at the vascular wall","volume":"107","author":"McEver","year":"2015","journal-title":"Cardiovasc. Res."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Dall\u2019Olio, F., Pucci, M., and Malagolini, N. (2021). The Cancer-Associated Antigens Sialyl Lewis(a\/x) and Sd(a): Two Opposite Faces of Terminal Glycosylation. Cancers, 13.","DOI":"10.3390\/cancers13215273"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s10719-020-09912-4","article-title":"The physiological and pathological roles and applications of sialyl Lewis x, a common carbohydrate ligand of the three selectins","volume":"37","author":"Jin","year":"2020","journal-title":"Glycoconj J."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1093\/glycob\/cwx105","article-title":"Selectins in cancer immunity","volume":"28","author":"Borsig","year":"2018","journal-title":"Glycobiology"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"7431","DOI":"10.7150\/thno.33858","article-title":"Carcinoembryonic antigen carrying SLe(X) as a new biomarker of more aggressive gastric carcinomas","volume":"9","author":"Gomes","year":"2019","journal-title":"Theranostics"},{"key":"ref_40","first-page":"33","article-title":"Involvement of a non-human sialic Acid in human cancer","volume":"4","author":"Samraj","year":"2014","journal-title":"Front. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"27199","DOI":"10.1074\/jbc.273.42.27199","article-title":"Identification of free deaminated sialic acid (2-keto-3-deoxy-D-glycero-D-galacto-nononic acid) in human red blood cells and its elevated expression in fetal cord red blood cells and ovarian cancer cells","volume":"273","author":"Inoue","year":"1998","journal-title":"J. Biol. Chem."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1093\/glycob\/cwv051","article-title":"LC\u2013MS\/MS glycomic analyses of free and conjugated forms of the sialic acids, Neu5Ac, Neu5Gc and KDN in human throat cancers","volume":"25","author":"Wang","year":"2015","journal-title":"Glycobiology"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1038\/nri3737","article-title":"Siglec-mediated regulation of immune cell function in disease","volume":"14","author":"Macauley","year":"2014","journal-title":"Nat. Rev. Immunol."},{"key":"ref_44","unstructured":"Varki, A., Cummings, R.D., Esko, J.D., Stanley, P., Hart, G.W., Aebi, M., Darvill, A.G., Kinoshita, T., Packer, N.H., and Prestegard, J.H. (2015). C-Type Lectins. Essentials of Glycobiology, Cold Spring Harbor Laboratory Press."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s00018-019-03288-x","article-title":"Sialic acid-binding immunoglobulin-like lectins (Siglecs) detect self-associated molecular patterns to regulate immune responses","volume":"77","author":"Varki","year":"2020","journal-title":"Cell Mol. Life Sci."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.3389\/fimmu.2018.02807","article-title":"Modulation of Immune Tolerance via Siglec-Sialic Acid Interactions","volume":"9","author":"Lubbers","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/nri.2018.3","article-title":"The tumour glyco-code as a novel immune checkpoint for immunotherapy","volume":"18","author":"Schetters","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/nrc3236","article-title":"Antibody therapy of cancer","volume":"12","author":"Scott","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Zahavi, D., and Weiner, L. (2020). Monoclonal Antibodies in Cancer Therapy. Antibodies, 9.","DOI":"10.3390\/antib9030034"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nri2744","article-title":"Monoclonal antibodies: Versatile platforms for cancer immunotherapy","volume":"10","author":"Weiner","year":"2010","journal-title":"Nat. Rev. Immunol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/nrd.2018.75","article-title":"The promise and challenges of immune agonist antibody development in cancer","volume":"17","author":"Mayes","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/244444a0","article-title":"Human x mouse somatic cell hybrid clone secreting immunoglobulins of both parental types","volume":"244","author":"Schwaber","year":"1973","journal-title":"Nature"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/256495a0","article-title":"Continuous cultures of fused cells secreting antibody of predefined specificity","volume":"256","author":"Milstein","year":"1975","journal-title":"Nature"},{"key":"ref_54","first-page":"315","article-title":"Phage display for the production of human monoclonal antibodies against human pathogens","volume":"27","author":"Mancini","year":"2004","journal-title":"New MicroBiol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"439","DOI":"10.2174\/138920108786786349","article-title":"Phage display derived therapeutic antibodies","volume":"9","author":"Thie","year":"2008","journal-title":"Curr. Pharm. Biotechnol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"256","DOI":"10.4161\/mabs.2.3.11641","article-title":"The immunogenicity of humanized and fully human antibodies: Residual immunogenicity resides in the CDR regions","volume":"2","author":"Harding","year":"2010","journal-title":"MAbs"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"100360","DOI":"10.1016\/j.esmoop.2021.100360","article-title":"Safety and efficacy of HER2 blockade by trastuzumab-based chemotherapy-containing combination strategies in HER2+ gastroesophageal adenocarcinoma","volume":"7","author":"Catenacci","year":"2021","journal-title":"ESMO Open"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1158\/0008-5472.CAN-03-2435","article-title":"Antibodies directed against Lewis-Y antigen inhibit signaling of Lewis-Y modified ErbB receptors","volume":"64","author":"Klinger","year":"2004","journal-title":"Cancer Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1038\/ni.3552","article-title":"The mucin MUC1 modulates the tumor immunological microenvironment through engagement of the lectin Siglec-9","volume":"17","author":"Beatson","year":"2016","journal-title":"Nat. Immunol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1016\/j.ymthe.2020.12.029","article-title":"Isoforms of MUC16 activate oncogenic signaling through EGF receptors to enhance the progression of pancreatic cancer","volume":"29","author":"Thomas","year":"2021","journal-title":"Mol. Ther."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1158\/1078-0432.CCR-20-3909","article-title":"Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032","volume":"27","author":"Yu","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1158\/2326-6066.CIR-18-0266","article-title":"A Mechanism of Resistance to Antibody-Targeted Immune Attack","volume":"7","author":"Aldeghaither","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1158\/1078-0432.CCR-17-2781","article-title":"Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: The AMNESIA Case-Control Study","volume":"24","author":"Pietrantonio","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1038\/bcj.2011.11","article-title":"The identification of irreversible rituximab-resistant lymphoma caused by CD20 gene mutations","volume":"1","author":"Mishima","year":"2011","journal-title":"Blood Cancer J."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Sickmier, E.A., Kurzeja, R.J., Michelsen, K., Vazir, M., Yang, E., and Tasker, A.S. (2016). The Panitumumab EGFR Complex Reveals a Binding Mechanism That Overcomes Cetuximab Induced Resistance. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0163366"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/j.addr.2008.04.012","article-title":"Antibody tumor penetration: Transport opposed by systemic and antigen-mediated clearance","volume":"60","author":"Thurber","year":"2008","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"7342","DOI":"10.1038\/s41388-019-0946-8","article-title":"Therapeutic anti-cancer activity of antibodies targeting sulfhydryl bond constrained epitopes on unglycosylated RON receptor tyrosine kinase","volume":"38","author":"Koh","year":"2019","journal-title":"Oncogene"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s12929-020-00670-x","article-title":"The impact of PD-L1\u2009N-linked glycosylation on cancer therapy and clinical diagnosis","volume":"27","author":"Wang","year":"2020","journal-title":"J. Biomed. Sci."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ccell.2019.06.008","article-title":"Removal of N-Linked Glycosylation Enhances PD-L1 Detection and Predicts Anti-PD-1\/PD-L1 Therapeutic Efficacy","volume":"36","author":"Lee","year":"2019","journal-title":"Cancer Cell"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1080\/07388551.2020.1869684","article-title":"Characterization of glycosylation in monoclonal antibodies and its importance in therapeutic antibody development","volume":"41","author":"Kaur","year":"2021","journal-title":"Crit. Rev. Biotechnol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"26733","DOI":"10.1074\/jbc.M202069200","article-title":"Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity","volume":"277","author":"Shields","year":"2002","journal-title":"J. Biol. Chem."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"5032","DOI":"10.1074\/jbc.M510171200","article-title":"The carbohydrate at FcgammaRIIIa Asn-162. An element required for high affinity binding to non-fucosylated IgG glycoforms","volume":"281","author":"Ferrara","year":"2006","journal-title":"J. Biol. Chem."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1016\/j.molimm.2006.09.005","article-title":"Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality","volume":"44","author":"Scallon","year":"2007","journal-title":"Mol. Immunol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1021\/bp050228w","article-title":"Control of recombinant monoclonal antibody effector functions by Fc N-glycan remodeling in vitro","volume":"21","author":"Hodoniczky","year":"2005","journal-title":"Biotechnol. Prog."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1093\/glycob\/cwr027","article-title":"High-mannose glycans on the Fc region of therapeutic IgG antibodies increase serum clearance in humans","volume":"21","author":"Goetze","year":"2011","journal-title":"Glycobiology"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Elshiaty, M., Schindler, H., and Christopoulos, P. (2021). Principles and Current Clinical Landscape of Multispecific Antibodies against Cancer. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22115632"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"12605","DOI":"10.1073\/pnas.1000976107","article-title":"T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells","volume":"107","author":"Lutterbuese","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1158\/1538-7445.AM10-3485","article-title":"Abstract 3485: MM-111, an ErbB2\/ErbB3 bispecific antibody with potent activity in ErbB2-overexpressing cells, positively combines with trastuzumab to inhibit growth of breast cancer cells driven by the ErbB2\/ErbB3 oncogenic unit","volume":"70","author":"Huhalov","year":"2010","journal-title":"Cancer Res."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41571-021-00470-8","article-title":"Unlocking the potential of antibody-drug conjugates for cancer therapy","volume":"18","author":"Drago","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Hafeez, U., Parakh, S., Gan, H.K., and Scott, A.M. (2020). Antibody-Drug Conjugates for Cancer Therapy. Molecules, 25.","DOI":"10.3390\/molecules25204764"},{"key":"ref_81","first-page":"1","article-title":"The Resurgence of Antibody Drug Conjugates in Cancer Therapeutics: Novel Targets and Payloads","volume":"40","author":"Boni","year":"2020","journal-title":"Am. Soc. Clin. Oncol. Educ Book"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41416-019-0635-y","article-title":"Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer","volume":"122","author":"Hunter","year":"2020","journal-title":"Br. J. Cancer"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","article-title":"Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): A two-arm, randomised, open-label, phase 2 study","volume":"21","author":"Lonial","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer","volume":"382","author":"Modi","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1056\/NEJMoa1814213","article-title":"Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer","volume":"380","author":"Bardia","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1080\/14712598.2021.1825678","article-title":"Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia in adults","volume":"21","author":"Goldenson","year":"2021","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.37765\/ajmc.2020.42400","article-title":"Cost-effectiveness of brentuximab vedotin with chemotherapy in treatment of CD30-expressing PTCL","volume":"26","author":"Feldman","year":"2020","journal-title":"Am. J. Manag. Care"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1200\/JCO.19.00172","article-title":"Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"38","author":"Sehn","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"10304","DOI":"10.1073\/pnas.1608069113","article-title":"Precision glycocalyx editing as a strategy for cancer immunotherapy","volume":"113","author":"Xiao","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.7150\/ijms.49801","article-title":"Application of Nanotechnology in Cancer Diagnosis and Therapy\u2014A Mini-Review","volume":"17","author":"Jin","year":"2020","journal-title":"Int. J. Med. Sci."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.semcancer.2020.01.011","article-title":"Targeting cancer cells with nanotherapeutics and nanodiagnostics: Current status and future perspectives","volume":"69","author":"Ali","year":"2021","journal-title":"Semin. Cancer Biol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.jconrel.2020.01.035","article-title":"Functionalizing nanoparticles with cancer-targeting antibodies: A comparison of strategies","volume":"320","author":"Marques","year":"2020","journal-title":"J. Control. Release"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-030-23765-3_1","article-title":"Current Development of Monoclonal Antibodies in Cancer Therapy","volume":"214","author":"Parakh","year":"2020","journal-title":"Recent Results Cancer Res."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.semcancer.2019.12.004","article-title":"Glyco-nanoparticles: New drug delivery systems in cancer therapy","volume":"69","author":"Khan","year":"2021","journal-title":"Semin. Cancer Biol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"120268","DOI":"10.1016\/j.ijpharm.2021.120268","article-title":"Antibody-mediated drug delivery","volume":"596","author":"Arslan","year":"2021","journal-title":"Int. J. Pharm."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1039\/C6SC02403C","article-title":"Antibody fragments as nanoparticle targeting ligands: A step in the right direction","volume":"8","author":"Richards","year":"2017","journal-title":"Chem. Sci."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.jconrel.2021.01.022","article-title":"Polymeric micelles targeted against CD44v6 receptor increase niclosamide efficacy against colorectal cancer stem cells and reduce circulating tumor cells in vivo","volume":"331","author":"Andrade","year":"2021","journal-title":"J. Control. Release"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1039\/D0BM00556H","article-title":"Effective intracellular delivery of bevacizumab via PEGylated polymeric nanoparticles targeting the CD44v6 receptor in colon cancer cells","volume":"8","author":"Sousa","year":"2020","journal-title":"Biomater Sci."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Torres-P\u00e9rez, S.A., Torres-P\u00e9rez, C.E., Pedraza-Escalona, M., P\u00e9rez-Tapia, S.M., and Ram\u00f3n-Gallegos, E. (2020). Glycosylated Nanoparticles for Cancer-Targeted Drug Delivery. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.605037"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ddtec.2021.02.001","article-title":"Gold nanoparticle-based platforms for vaccine development","volume":"38","author":"Lay","year":"2020","journal-title":"Drug Discov. Today Technol."},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Anderluh, M., Berti, F., Bzducha-Wr\u00f3bel, A., Chiodo, F., Colombo, C., Compostella, F., Durlik, K., Ferhati, X., Holmdahl, R., and Jovanovic, D. (2021). Recent advances on smart glycoconjugate vaccines in infections and cancer. FEBS J.","DOI":"10.1111\/febs.15909"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2147\/IJN.S273883","article-title":"The Adjuvant of \u03b1-Galactosylceramide Presented by Gold Nanoparticles Enhances Antitumor Immune Responses of MUC1 Antigen-Based Tumor Vaccines","volume":"16","author":"Liu","year":"2021","journal-title":"Int. J. Nanomed."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.bmc.2016.01.044","article-title":"Glycopeptide-functionalized gold nanoparticles for antibody induction against the tumor associated mucin-1 glycoprotein","volume":"24","author":"Cai","year":"2016","journal-title":"Bioorg. Med. Chem."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"583","DOI":"10.7150\/jca.11567","article-title":"In Vitro Administration of Gold Nanoparticles Functionalized with MUC-1 Protein Fragment Generates Anticancer Vaccine Response via Macrophage Activation and Polarization Mechanism","volume":"6","author":"Mocan","year":"2015","journal-title":"J. Cancer"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"9362","DOI":"10.1021\/ja4046857","article-title":"\u2018Multicopy multivalent\u2019 glycopolymer-stabilized gold nanoparticles as potential synthetic cancer vaccines","volume":"135","author":"Parry","year":"2013","journal-title":"J. Am. Chem. Soc."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1021\/acsbiomedchemau.1c00021","article-title":"A Stable Gold Nanoparticle-Based Vaccine for the Targeted Delivery of Tumor-Associated Glycopeptide Antigens","volume":"1","author":"Trabbic","year":"2021","journal-title":"ACS Bio Med. Chem. Au"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1007\/s11095-011-0459-9","article-title":"Activation of antigen-specific T cell-responses by mannan-decorated PLGA nanoparticles","volume":"28","author":"Hamdy","year":"2011","journal-title":"Pharm. Res."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.2147\/IJN.S207589","article-title":"Drug-free mannosylated liposomes inhibit tumor growth by promoting the polarization of tumor-associated macrophages","volume":"14","author":"Ye","year":"2019","journal-title":"Int. J. Nanomed."},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Yu, C., Hu, Y., Duan, J., Yuan, W., Wang, C., Xu, H., and Yang, X.D. (2011). Novel aptamer-nanoparticle bioconjugates enhances delivery of anticancer drug to MUC1-positive cancer cells in vitro. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0024077"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.ijpharm.2014.05.041","article-title":"MUC1 aptamer conjugated to chitosan nanoparticles, an efficient targeted carrier designed for anticancer SN38 delivery","volume":"473","author":"Sayari","year":"2014","journal-title":"Int. J. Pharm."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1080\/03639045.2017.1371734","article-title":"MUC1 aptamer-conjugated mesoporous silica nanoparticles effectively target breast cancer cells","volume":"44","author":"Taghdisi","year":"2018","journal-title":"Drug Dev. Ind. Pharm."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1021\/acs.molpharmaceut.7b00900","article-title":"Evaluation of MUC1-Aptamer Functionalized Hybrid Nanoparticles for Targeted Delivery of miRNA-29b to Nonsmall Cell Lung Cancer","volume":"15","author":"Perepelyuk","year":"2018","journal-title":"Mol. Pharm."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1038\/s41467-021-22555-9","article-title":"Machine learning guided aptamer refinement and discovery","volume":"12","author":"Bashir","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"21","DOI":"10.29252\/ibj.23.1.21","article-title":"Anti-Mucin1 Aptamer-Conjugated Chitosan Nanoparticles for Targeted Co-Delivery of Docetaxel and IGF-1R siRNA to SKBR3 Metastatic Breast Cancer Cells","volume":"23","author":"Jafari","year":"2019","journal-title":"Iran. Biomed. J."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/B978-0-12-800092-2.00011-3","article-title":"Advances and advantages of nanomedicine in the pharmacological targeting of hyaluronan-CD44 interactions and signaling in cancer","volume":"123","author":"Skandalis","year":"2014","journal-title":"Adv. Cancer Res."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1039\/D0BM00015A","article-title":"Delivery of dual miRNA through CD44-targeted mesoporous silica nanoparticles for enhanced and effective triple-negative breast cancer therapy","volume":"8","author":"Ahir","year":"2020","journal-title":"Biomater. Sci."},{"key":"ref_118","first-page":"433","article-title":"Self-crosslinkable chitosan-hyaluronic acid dialdehyde nanoparticles for CD44-targeted siRNA delivery to treat bladder cancer","volume":"6","author":"Liang","year":"2021","journal-title":"Bioact. Mater."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.actbio.2018.09.043","article-title":"Fab-conjugated PLGA nanoparticles effectively target cancer cells expressing human CD44v6","volume":"81","author":"Kennedy","year":"2018","journal-title":"Acta Biomater."},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Correa, T.D.S., Bocca, A.L., Figueiredo, F., Lima, E.C.O., Almeida Santos, M.F.M., Lacava, Z.G.M., and Campos-da-Paz, M. (2021). Anti-CEA tagged iron nanoparticles for targeting triple-negative breast cancer. Biomed. Mater.","DOI":"10.1088\/1748-605X\/abe359"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.ijpharm.2018.08.016","article-title":"Carcinoembryonic antigen-targeted nanoparticles potentiate the delivery of anticancer drugs to colorectal cancer cells","volume":"549","author":"Pereira","year":"2018","journal-title":"Int. J. Pharm."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"118646","DOI":"10.1016\/j.ijpharm.2019.118646","article-title":"Glycoengineered nanoparticles enhance the delivery of 5-fluoroucil and paclitaxel to gastric cancer cells of high metastatic potential","volume":"570","author":"Fernandes","year":"2019","journal-title":"Int. J. Pharm."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"e2000377","DOI":"10.1002\/mabi.202000377","article-title":"Development and Characterization of PLGA-Based Multistage Delivery System for Enhanced Payload Delivery to Targeted Vascular Endothelium","volume":"21","author":"Fuentes","year":"2021","journal-title":"Macromol. Biosci."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.18632\/oncotarget.28054","article-title":"Nanoparticle T cell engagers for the treatment of acute myeloid leukemia","volume":"12","author":"Alhallak","year":"2021","journal-title":"Oncotarget"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.biomaterials.2018.03.025","article-title":"Lanthanide-doped nanoparticles conjugated with an anti-CD33 antibody and a p53-activating peptide for acute myeloid leukemia therapy","volume":"167","author":"Niu","year":"2018","journal-title":"Biomaterials"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrd3003","article-title":"The safety and side effects of monoclonal antibodies","volume":"9","author":"Hansel","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1021\/mp5008212","article-title":"CD33-Targeted Lipid Nanoparticles (aCD33LNs) for Therapeutic Delivery of GTI-2040 to Acute Myelogenous Leukemia","volume":"12","author":"Li","year":"2015","journal-title":"Mol. Pharm."},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Chen, W.C., Kawasaki, N., Nycholat, C.M., Han, S., Pilotte, J., Crocker, P.R., and Paulson, J.C. (2012). Antigen delivery to macrophages using liposomal nanoparticles targeting sialoadhesin\/CD169. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0039039"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.actbio.2017.11.007","article-title":"Lectin-conjugated pH-responsive mesoporous silica nanoparticles for targeted bone cancer treatment","volume":"65","author":"Lozano","year":"2018","journal-title":"Acta Biomater."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"102068","DOI":"10.1016\/j.nano.2019.102068","article-title":"Enhanced anti-colon cancer efficacy of 5-fluorouracil by epigallocatechin-3- gallate co-loaded in wheat germ agglutinin-conjugated nanoparticles","volume":"21","author":"Wang","year":"2019","journal-title":"Nanomedicine"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1039\/C7NR06415B","article-title":"Lectin-gated and glycan functionalized mesoporous silica nanocontainers for targeting cancer cells overexpressing Lewis X antigen","volume":"10","author":"Bhat","year":"2017","journal-title":"Nanoscale"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.bbagen.2017.01.015","article-title":"Formulation of liposomes functionalized with Lotus lectin and effective in targeting highly proliferative cells","volume":"1861","author":"Capone","year":"2017","journal-title":"Biochim. Biophys. Acta Gen. Subj."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.aca.2018.04.029","article-title":"Multifunctional GQDs-Concanavalin A@Fe3O4 nanocomposites for cancer cells detection and targeted drug delivery","volume":"1027","author":"Ganganboina","year":"2018","journal-title":"Anal. Chim. Acta"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/4\/911\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:18:11Z","timestamp":1760134691000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/4\/911"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,12]]},"references-count":133,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,2]]}},"alternative-id":["cancers14040911"],"URL":"https:\/\/doi.org\/10.3390\/cancers14040911","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,12]]}}}